FDA Approves Mimrylo as First-of-Its-Kind Treatment for Polycythemia Vera
The Food and Drug Administration approved rusfertide, a weekly injectable therapy developed by Protagonist Therapeutics and commercialized by Takeda under the brand name Mimrylo, to treat polycythemia vera. This rare … Read More